Akorn (NASDAQ:AKRX) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Akorn to post earnings of ($0.11) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
Akorn (NASDAQ:AKRX) last announced its quarterly earnings data on Thursday, February 28th. The company reported ($0.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.31). The firm had revenue of $153.39 million for the quarter, compared to analysts’ expectations of $164.75 million. Akorn had a negative return on equity of 13.34% and a negative net margin of 57.91%. The firm’s quarterly revenue was down 17.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 EPS. On average, analysts expect Akorn to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of Akorn stock opened at $2.85 on Friday. The firm has a market cap of $357.90 million, a price-to-earnings ratio of -7.92 and a beta of 2.61. The company has a quick ratio of 2.40, a current ratio of 3.42 and a debt-to-equity ratio of 1.85. Akorn has a one year low of $2.64 and a one year high of $19.65.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/05/akorn-akrx-set-to-announce-quarterly-earnings-on-tuesday.html.
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
See Also: What is an overbought condition?
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.